Allergy, Asthma and Clinical Research Center | Oklahoma City, OK

Research site

(Unclaimed)

Location

4200 W Memorial Road, Suite 206, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

azelastine hydrochloride

Dupilumab

Omalizumab

azelastineHcl

fluticasone propionate

Levalbuterol

azelastine Hcl

Mometasone furoate

Aerovant

DUPIXENT®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 21 total trials

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Enrolling

Wheezing Lower Respiratory Illness

Recurrent Wheezing

Drug: Placebo

Drug: OM-85

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis (ENGAGE)

The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or...

Enrolling

Eosinophilic Gastrointestinal Disease

Eosinophilic Gastritis

Drug: Dupilumab Dose 2

Drug: Matching Placebo

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients (EVEREST)

Primary Objective-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smellSecondary Objec...

Active, not recruiting

Asthma

Chronic Rhinosinusitis With Nasal Polyps

Drug: Omalizumab

Drug: Placebo

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (AERIFY-3)

This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Itepekimab SAR440340

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Inhaled Long-Acting Muscarinic Antagonist